Non-Functioning Parathyroid Carcinoma: A Case Report

Merlano, Marco; Conte, P.F.; Scarsi, Pietro; R, Tatarek; Barbieri, Andrea; Santelli, A.; Scarpati, D; Angelis, P De

doi:10.1177/030089168507100216

Cited by 18 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…massNoNormalNormalExtensive?Merlano et al [14]59/MNeck mass, VCP, dysphagia, axillary LNNo (adenoma w/high Ml)NormalNormal8x6x4YesYamashita et al [15]69/FNeck massNo (thyroid carcinoma)9.3?5x4x3?Hickey et al [16–18]27/MNeck massNo (cystic thyroid mass)9.2-9.8?5.5?49/MNeck massNo????59/MNeck massNo (follicular thyroid ca)9.5?2.5YesChahinian et al [19]69/FNeck mass, pleural effusionNoNormalNormal2x2, 14?Dhom and Hohbach [20]38/MNeck massNo (thyroid nodule)Normal?2.5x1.5?Altenahr and Saeger [21]50/MNeck massNo (thyroid tumor)Normal??YesPachter and Lattes [22]50/FChest painNoNormal…”

Section: Non-functional Parathyroid Carcinomamentioning

confidence: 99%

Non-Functional Parathyroid Carcinoma: A Review of the Literature and Report of a Case Requiring Extensive Surgery

Wilkins

Lewis

2009

Head and Neck Pathol

View full text Add to dashboard Cite

Parathyroid carcinoma is a rare malignancy, and only accounts for 0.5–2% of cases of primary hyperparathyroidism. Less than 10% of parathyroid carcinomas are non-functional, and as such, they have been rarely reported in the literature. Importantly, margin status at resection is related to prognosis, and only a handful of case reports of non-functional carcinoma note this important parameter. Here we report the first case of non-functional parathyroid carcinoma with negative margins, and review the literature on this rare entity. Whether functional or non-functional, parathyroid carcinoma can often be difficult to differentiate from benign parathyroid adenoma. While diagnosis has been based on clinical and histological criteria, recent data concerning the molecular underpinnings of parathyroid carcinoma may allow for improved accuracy in distinguishing benign and malignant parathyroid tumors.

show abstract

Section: Non-functional Parathyroid Carcinomamentioning

confidence: 99%

Non-Functional Parathyroid Carcinoma: A Review of the Literature and Report of a Case Requiring Extensive Surgery

Wilkins

Lewis

2009

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…Death in patients with non‐functioning parathyroid carcinoma is primarily due to the volume of regional disease and metastases70. Few patients survive longer than 2 years69, 71.…”

Section: Non‐functioning Parathyroid Carcinomamentioning

confidence: 99%

Parathyroid carcinoma

Rawat

Khetan

Williams

et al. 2005

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…5a and b, a 264 bp IL-6 amplicon was present in six cultured parathyroids from five individuals with a clinical diagnosis of adenoma (samples 1, 3, 4, 20, 21 and 23), one gland from a patient with MEN-I (sample 2), one gland from an individual with primary hyperplasia (sample 19) and 6 glands from four patients with secondary hyperplasia (samples 5-8, 9-11, 12-14 and 15-18). In contrast, detection of IL-6 mRNA from 14 parathyroid glands collected ex vivo from nine individuals and frozen immediately after resection (samples [25][26][27][28][29][30][31][32][33][34][35][36][37][38] showed a much lower frequency of positivity and intensity of signal (Fig. 5b), suggesting amplification and/or induction of IL-6 production upon culture initiation.…”

Section: Il-6 Mrna Expression In Cultured Parathyroids and In Frozen mentioning

confidence: 99%

Interleukin-6 production and secretion by human parathyroids

Safley¹,

Villinger

Jackson³

et al. 2004

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYParathyroid hormone (PTH) stimulates osteoblasts to produce the proinflammatory cytokine interleukin-6 (IL-6), causing bone resorption. In patients with primary hyperparathyroidism, elevated serum levels of IL-6 normalize after resection of parathyroid tumours. Because IL-6 is also expressed in normal parathyroids and in other endocrine cells (adrenal and islet), we hypothesized that parathyroid tumours might contribute directly to the elevated serum IL-6 levels in patients with hyperparathyroidism. Immunohistochemistry identified IL-6, PTH, and chromogranin-A (an endocrine and neuroendocrine tumour marker) in normal, adenomatous and hyperplastic parathyroids. Using immunofluorescence and confocal microscopy, IL-6 co-localized with PTH and with chromogranin-A in parathyroid cells. All cultured parathyroid tumours secreted IL-6 at levels markedly higher than optimally stimulated peripheral blood mononuclear cells. Supernates from cultured parathyroids stimulated proliferation of an IL-6-dependent cell line, and anti-IL-6 MoAb abolished this stimulatory effect. IL-6 mRNA was documented in cultured parathyroid tumours, cultured normal parathyroids, fresh operative parathyroid tumours and fresh operative normal specimens. In conclusion, these data show that parathyroid tumours and normal parathyroids contain, produce and secrete IL-6. Our findings present a novel pathway by which human parathyroids may contribute markedly to IL-6 production and elevation of serum IL-6 levels in patients with hyperparathyroidism. The physiological relevance of IL-6 production by human parathyroids remains to be determined, but IL-6 secretion by parathyroid tumours may contribute to bone loss and to other multi-system complaints observed in these patients.

show abstract

Non-Functioning Parathyroid Carcinoma: A Case Report

Cited by 18 publications

References 7 publications

Non-Functional Parathyroid Carcinoma: A Review of the Literature and Report of a Case Requiring Extensive Surgery

Non-Functional Parathyroid Carcinoma: A Review of the Literature and Report of a Case Requiring Extensive Surgery

Parathyroid carcinoma

Interleukin-6 production and secretion by human parathyroids

Contact Info

Product

Resources

About